XLO Xilio Therapeutics, Inc.
Healthcare$8.35+1.21%ClosedMarket Cap: $50.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
18.59
P/S
0.92
EV/EBITDA
2.31
DCF Value
$34.66
FCF Yield
-116.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.7%
Operating Margin
-79.0%
Net Margin
-58.5%
ROE
-117.2%
ROA
-19.1%
ROIC
-34.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $12.6M | 97.3% | $-14.1M | $-9.5M | $— | — |
| Q4 null | $13.7M | 100.0% | $-11.8M | $10.4M | $— | — |
| FY null | $43.8M | 96.5% | $-42.0M | $-35.0M | $— | — |
| Q3 null | $19.1M | 100.0% | $-1.9M | $-16.3M | $— | — |
| Q2 null | $8.1M | -89.6% | $-14.4M | $-15.8M | $— | — |
| Q1 null | $2.9M | 100.0% | $-13.9M | $-13.3M | $— | — |
| Q4 null | $1.7M | 100.0% | $-13.6M | $-13.1M | $— | — |
| FY null | $6.3M | 100.0% | $-60.6M | $-58.2M | $— | — |
| Q3 null | $2.3M | 100.0% | $-14.8M | $-14.0M | $— | — |
| Q2 null | $2.4M | 100.0% | $-14.7M | $-13.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-17.5M | $-17.2M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-18.1M | $-17.7M | $-8.96 | — |